Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute.
The National Cancer Institute and the University of Alabama are developing radiolabeled humanized versions of the anticarcinoma monoclonal antibody CC49 devoid of the CH2 domain (designated HuCC49 delta CH2). The antibody is currently undergoing phase I trials for the potential treatment of various tumors.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000008:administration & dosage* / Q000235:genetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D006801:Humans; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods*; D014481:United States
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; C091202:B72.3 antibody